age-reversal
(2)
Rejuvenation Technologies Inc.
Rejuvenation Technologies is a Stanford-spun biotech developing modified-mRNA therapeutics that temporarily switch on telomerase to lengthen telomeres and reverse cellular aging in specific tissues. Its lead programs target fibrotic and age-related diseases such as pulmonary fibrosis, chronic liver disease and bone-marrow failure, delivered by proprietary tissue-targeted lipid nanoparticles. Backed by Khosla Ventures and Y Combinator, the company holds 50+ patents and is advancing toward Phase I clinical readouts.
John Ramunas
John Ramunas, PhD, is the Co-Founder and CEO of Rejuvenation Technologies Inc., a Mountain View, CA biotechnology company pioneering mRNA-based telomere extension therapy to reverse cellular aging. A serial entrepreneur turned neuroscientist, Ramunas spent his PhD at Stanford's Baxter Laboratory for Stem Cell Biology inventing the first safe, nonimmunogenic TERT mRNA drug - a technology now protected by 50+ patents. His company, backed by Khosla Ventures and Y Combinator, is advancing a pipeline targeting fatal orphan diseases including idiopathic pulmonary fibrosis and liver cirrhosis, with the long-term vision of a single therapy taken every few years to prevent age-related disease.